ビンカアルカロイド原薬の世界市場レポート 2025年

ビンカアルカロイド原薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.4％で18億米ドルに成長します。予測期間における成長の原動力は、小児がんの有病率の増加、費用対効果の高い化学療法への需要の高まり、低侵襲がん治療への重点化、獣医がん学におけるビンカアルカロイドの使用拡大、がん治療薬のパイプラインの増加です。予測期間における主な動向としては、半合成生産技術の発展、毒性を低減した高度な製剤の開発、ビンカアルカロイドの標的デリバリーにおける革新、がん治療薬の創薬における人工知能（AI）の統合、がん治療薬に特化した受託製造の進歩などが挙げられます。

がんの罹患率の上昇は、今後数年間のビンカアルカロイド原薬市場の成長を牽引すると予想されます。がんは、異常な細胞の無秩序な増殖と拡散を特徴とし、高齢化により蔓延しつつあります。加齢に伴い、遺伝子変異が蓄積され、免疫機能が低下するため、がんの開発リスクが高まる。ビンカアルカロイド原薬は、細胞分裂を阻害することにより、急速に成長する腫瘍に効果を発揮し、がん治療において重要な役割を果たしています。これらのAPIは微小管を標的とすることで化学療法レジメンを強化し、治療成績を向上させる。例えば、オーストラリア保健福祉研究所によると、2024年7月、オーストラリアにおける2022年のがん診断件数は16万570件となり、2021年から3,789件増加しました。したがって、がんの罹患率の上昇がビンカアルカロイド原薬市場の成長を牽引しています。

ヘルスケア支出の増加もビンカアルカロイドAPI市場の成長を促進すると予想されます。ヘルスケア支出とは、医療サービス、治療、研究、健康状態を維持・改善するための公衆衛生の取り組みに対する支出総額を指します。ヘルスケアサービスに対する需要の高まりは、主に高価で長期的な治療を必要とするがんなどの慢性疾患の負担増によってもたらされています。ヘルスケア支出の増加は、ビンカアルカロイド原薬の生産と研究に資金を供給し、必要不可欠ながん治療薬の供給を確保するのに役立っています。このような投資によって製剤の技術革新が促進され、治療成績の向上や個別化医療の進歩がもたらされます。例えば、メディケア＆メディケイド・サービスセンター（CMS）によると、米国の国民医療費は2023年に7.5％増の4兆9,000億米ドルに達し、同国のGDPの17.6％を占めました。ヘルスケア支出は2023年から2032年まで年平均5.6%で成長し続け、ビンカアルカロイド原薬市場をさらに下支えすると予測されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ビンカアルカロイド原薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のビンカアルカロイド原薬市場：成長率分析
• 世界のビンカアルカロイド原薬市場の実績：規模と成長, 2019-2024
• 世界のビンカアルカロイド原薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ビンカアルカロイド原薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のビンカアルカロイド原薬市場ビンカアルカロイドの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビンクリスチン
• ビンブラスチン
• ビンデシン
• ビノレルビン
• その他の種類のビンカアルカロイド
• 世界のビンカアルカロイド原薬市場処方タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 無菌製剤
• 非滅菌製剤
• 世界のビンカアルカロイド原薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺がん
• 乳がん
• リンパ腫
• その他の用途
• 世界のビンカアルカロイド原薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製薬会社
• 調査機関
• 契約開発製造組織（CDMO）
• 腫瘍学クリニック
• 世界のビンカアルカロイド原薬市場ビンクリスチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビンクリスチン硫酸塩注射液
• 経口用ビンクリスチン硫酸塩
• ビンクリスチン硫酸塩注射剤（凍結乾燥）
• 世界のビンカアルカロイド原薬市場ビンブラスチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビンブラスチン硫酸塩注射液
• ビンブラスチン硫酸塩経口錠
• 注射用硫酸ビンブラスチン（凍結乾燥）
• 世界のビンカアルカロイド原薬市場、ビンデシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビンデシン硫酸塩注射液
• 経口用硫酸ビンデシン
• 世界のビンカアルカロイド原薬市場ビノレルビンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酒石酸ビノレルビン注射剤
• ビノレルビン酒石酸塩経口カプセル
• 世界のビンカアルカロイド原薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビンクリスチン類似体
• ビンブラスチン類似体
• その他のビンカアルカロイド

第7章 地域別・国別分析

• 世界のビンカアルカロイド原薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のビンカアルカロイド原薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ビンカアルカロイド原薬市場：競合情勢
• ビンカアルカロイド原薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • Gedeon Richter Plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Zhejiang Hisun Pharmaceutical Co. Ltd.
• Pierre Fabre Laboratories
• Qilu Pharmaceutical Co. Ltd.
• Minakem SAS
• Taj Pharmaceuticals Ltd.
• Naprod Life Sciences Pvt. Ltd.
• Guangzhou Hanfang Pharmaceutical Co. Ltd.
• ChemWerth Inc.
• Transo-Pharm USA LLC
• Sun Pharmaceutical Industries Ltd.
• Avanscure Lifesciences Private Limited
• Zeon Pharma Industries India Private Limited
• Heet Healthcare Pvt. Ltd.
• Hubei Honch Pharmaceutical Co. Ltd.
• Hainan Periwinkle Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ビンカアルカロイド原薬市場2029：新たな機会を提供する国
• ビンカアルカロイド原薬市場2029：新たな機会を提供するセグメント
• ビンカアルカロイド原薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vinca alkaloid active pharmaceutical ingredients (APIs) refer to biologically active compounds derived from the Vinca plant, used in cancer treatment drugs. These alkaloids function by disrupting the mitotic process in cancer cells, preventing them from dividing and proliferating, which makes them essential in chemotherapy treatments.

The main types of vinca alkaloid APIs include vincristine, vinblastine, vindesine, vinorelbine, and others. Vincristine is a vinca alkaloid chemotherapy drug derived from the Catharanthus roseus plant. It acts as an antimitotic agent by binding to tubulin and inhibiting microtubule formation, thus blocking cell division. The formulations are available in both sterile and non-sterile preparations. Applications include treating lung cancer, breast cancer, lymphoma, and other oncology-related conditions. The end users include pharmaceutical companies, research institutions, contract development and manufacturing organizations (CDMOs), and oncology clinics.

The vinca alkaloid active pharmaceutical ingredient (API) market research report is one of a series of new reports from The Business Research Company that provides vinca alkaloid active pharmaceutical ingredient (API) market statistics, including vinca alkaloid active pharmaceutical ingredient (API) industry global market size, regional shares, competitors with a vinca alkaloid active pharmaceutical ingredient (API) market share, detailed vinca alkaloid active pharmaceutical ingredient (API) market segments, market trends and opportunities, and any further data you may need to thrive in the vinca alkaloid active pharmaceutical ingredient (API) industry. This vinca alkaloid active pharmaceutical ingredient (API) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vinca alkaloid active pharmaceutical ingredient (API) market size has grown strongly in recent years. It will grow from $1.25 billion in 2024 to $1.35 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historical period can be attributed to improved access to healthcare infrastructure, increased government support for cancer care, greater availability of generic cancer active pharmaceutical ingredients (APIs), rising collaborations among pharmaceutical companies, and a growing prevalence of lifestyle-related cancers.

The vinca alkaloid active pharmaceutical ingredient (API) market size is expected to see strong growth in the next few years. It will grow to $1.80 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period is driven by the increasing prevalence of pediatric cancers, rising demand for cost-effective chemotherapy, a growing emphasis on minimally invasive cancer treatments, the expanding use of vinca alkaloids in veterinary oncology, and the increasing pipeline of oncology drugs. Key trends in the forecast period include advancements in semi-synthetic production techniques, development of advanced formulations with reduced toxicity, innovation in targeted delivery of vinca alkaloids, the integration of artificial intelligence (AI) in oncology drug discovery, and advancements in oncology-specific contract manufacturing.

The rising incidence of cancer is expected to drive the growth of the vinca alkaloid active pharmaceutical ingredient (API) market in the coming years. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is becoming more prevalent due to the aging population. As individuals age, they accumulate genetic mutations and experience a decline in immune function, increasing their risk of developing cancer. Vinca alkaloid APIs play a critical role in cancer treatment by disrupting cell division, making them effective against rapidly growing tumors. These APIs enhance chemotherapy regimens by targeting microtubules, improving treatment outcomes. For example, according to the Australian Institute of Health and Welfare, in July 2024, cancer diagnoses in Australia increased to 160,570 cases in 2022, up by 3,789 cases from 2021. The rising incidence of cancer is, therefore, driving the growth of the vinca alkaloid API market.

The increasing healthcare expenditure is also expected to propel the growth of the vinca alkaloid API market. Healthcare expenditure refers to the total spending on medical services, treatments, research, and public health initiatives to maintain or improve health outcomes. The rising demand for healthcare services is mainly driven by the growing burden of chronic diseases such as cancer, which require expensive, long-term treatments. Increased healthcare spending helps fund the production and research of vinca alkaloid APIs, ensuring the availability of essential cancer treatments. This investment drives innovation in drug formulations, resulting in improved therapeutic outcomes and advancements in personalized medicine. For instance, according to the Centers for Medicare & Medicaid Services (CMS), national health expenditures in the U.S. grew by 7.5% in 2023, reaching \$4.9 trillion, which accounted for 17.6% of the country's GDP. It is projected that healthcare spending will continue to grow at an average annual rate of 5.6% from 2023 to 2032, further supporting the vinca alkaloid API market.

Companies operating in the vinca alkaloid API market are also focusing on developing advanced formulations to improve patient compliance and enhance treatment efficacy. One such advancement is the use of soft gel capsules, which help increase drug absorption and extend product life cycles. In December 2022, Adalvo Limited, a Malta-based pharmaceutical company, launched Vinorelbine soft gel capsules. Derived from the reference brand NAVELBINE, this formulation is used to treat non-small cell lung cancer and advanced breast cancer. By offering more convenient dosing options, soft gel capsules aim to improve treatment accessibility and patient compliance.

Major players in the vinca alkaloid active pharmaceutical ingredient (api) market are Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Gedeon Richter Plc, Zhejiang Hisun Pharmaceutical Co. Ltd., Pierre Fabre Laboratories, Qilu Pharmaceutical Co. Ltd., Minakem SAS, Taj Pharmaceuticals Ltd., Naprod Life Sciences Pvt. Ltd., Guangzhou Hanfang Pharmaceutical Co. Ltd., ChemWerth Inc., Transo-Pharm USA LLC, Sun Pharmaceutical Industries Ltd., Avanscure Lifesciences Private Limited, Zeon Pharma Industries India Private Limited, Heet Healthcare Pvt. Ltd., Hubei Honch Pharmaceutical Co. Ltd., Hainan Periwinkle Pharmaceutical Co. Ltd.

North America was the largest region in the vinca alkaloid active pharmaceutical ingredient (API) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vinca alkaloid active pharmaceutical ingredient (API) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vinca alkaloid active pharmaceutical ingredient (API) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vinca alkaloid active pharmaceutical ingredient (API) market consists of sales of leurocristine, episil, desacetylvinblastine, catharanthine, and vinflunine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vinca Alkaloid Active Pharmaceutical Ingredient (API) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vinca alkaloid active pharmaceutical ingredient (api) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vinca alkaloid active pharmaceutical ingredient (api) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vinca alkaloid active pharmaceutical ingredient (api) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Vinca Alkaloid: Vincristine; Vinblastine; Vindesine; Vinorelbine; Other Types Of Vinca Alkaloid
• 2) By Formulation Type: Sterile Formulations; Non-Sterile Formulations
• 3) By Application: Lung Cancer; Breast Cancer; Lymphoma; Other Applications
• 4) By End User: Pharmaceutical Companies; Research Institutions; Contract Development And Manufacturing Organizations (CDMOs); Oncology Clinics
• Subsegments:
• 1) By Vincristine: Vincristine Sulfate Injection; Vincristine Sulfate For Oral Use; Vincristine Sulfate For Injection, Lyophilized
• 2) By Vinblastine: Vinblastine Sulfate Injection; Vinblastine Sulfate Oral Tablets; Vinblastine Sulfate For Injection, Lyophilized
• 3) By Vindesine: Vindesine Sulfate Injection; Vindesine Sulfate For Oral Use
• 4) By Vinorelbine: Vinorelbine Tartrate Injection; Vinorelbine Tartrate Oral Capsules
• 5) By Other Types: Vincristine Analogues; Vinblastine Analogues; Other Vinca Alkaloids
• Companies Mentioned: Pfizer Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Gedeon Richter Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Characteristics

3. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Trends And Strategies

4. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Growth Rate Analysis
• 5.4. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Total Addressable Market (TAM)

6. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Segmentation

• 6.1. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vincristine
• Vinblastine
• Vindesine
• Vinorelbine
• Other Types Of Vinca Alkaloid
• 6.2. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sterile Formulations
• Non-Sterile Formulations
• 6.3. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Lymphoma
• Other Applications
• 6.4. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Research Institutions
• Contract Development And Manufacturing Organizations (CDMOs)
• Oncology Clinics
• 6.5. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Vincristine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vincristine Sulfate Injection
• Vincristine Sulfate For Oral Use
• Vincristine Sulfate For Injection, Lyophilized
• 6.6. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Vinblastine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vinblastine Sulfate Injection
• Vinblastine Sulfate Oral Tablets
• Vinblastine Sulfate For Injection, Lyophilized
• 6.7. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Vindesine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vindesine Sulfate Injection
• Vindesine Sulfate For Oral Use
• 6.8. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Vinorelbine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vinorelbine Tartrate Injection
• Vinorelbine Tartrate Oral Capsules
• 6.9. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vincristine Analogues
• Vinblastine Analogues
• Other Vinca Alkaloids

7. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Regional And Country Analysis

• 7.1. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 8.1. Asia-Pacific Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 9.1. China Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 9.2. China Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 10.1. India Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 11.1. Japan Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 11.2. Japan Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 12.1. Australia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 13.1. Indonesia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 14.1. South Korea Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 14.2. South Korea Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 15.1. Western Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 15.2. Western Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 16.1. UK Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 17.1. Germany Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 18.1. France Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 19.1. Italy Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 20.1. Spain Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 21.1. Eastern Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 21.2. Eastern Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 22.1. Russia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 23.1. North America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 23.2. North America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 24.1. USA Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 24.2. USA Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 25.1. Canada Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 25.2. Canada Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 26.1. South America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 26.2. South America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 27.1. Brazil Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 28.1. Middle East Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 28.2. Middle East Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

• 29.1. Africa Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Overview
• 29.2. Africa Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Type Of Vinca Alkaloid, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Competitive Landscape And Company Profiles

• 30.1. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Competitive Landscape
• 30.2. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Gedeon Richter Plc Overview, Products and Services, Strategy and Financial Analysis

31. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Other Major And Innovative Companies

• 31.1. Zhejiang Hisun Pharmaceutical Co. Ltd.
• 31.2. Pierre Fabre Laboratories
• 31.3. Qilu Pharmaceutical Co. Ltd.
• 31.4. Minakem SAS
• 31.5. Taj Pharmaceuticals Ltd.
• 31.6. Naprod Life Sciences Pvt. Ltd.
• 31.7. Guangzhou Hanfang Pharmaceutical Co. Ltd.
• 31.8. ChemWerth Inc.
• 31.9. Transo-Pharm USA LLC
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Avanscure Lifesciences Private Limited
• 31.12. Zeon Pharma Industries India Private Limited
• 31.13. Heet Healthcare Pvt. Ltd.
• 31.14. Hubei Honch Pharmaceutical Co. Ltd.
• 31.15. Hainan Periwinkle Pharmaceutical Co. Ltd.

32. Global Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

34. Recent Developments In The Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market

35. Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market High Potential Countries, Segments and Strategies

• 35.1 Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vinca Alkaloid Active Pharmaceutical Ingredient (API) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer